|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,549,770: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,549,770, granted on December 22, 1970, to The Upjohn Company, pertains to a class of pharmaceutical compounds primarily used as anti-inflammatory and analgesic agents. The patent encompasses a broad range of compounds characterized by a specific chemical structure and claims methods of synthesis and therapeutic use. This document provides an in-depth examination of the patent's scope, its claims, and an overview of the patent landscape surrounding similar pharmacological inventions.
Scope of U.S. Patent 3,549,770
Temporal and Geographical Scope
-
Filing and Grant Dates:
Filed on January 28, 1968, and granted in 1970, the patent's term would generally extend to 17 years from the grant date, i.e., until December 22, 1987, subject to maintenance and jurisdictional lapses.
-
Jurisdiction:
Patent rights are territorial and apply exclusively within the United States.
Chemical Scope
-
Core Structure:
The patent claims a class of 2-aryl-2-oxo-1,3-dioxolanes and analogous compounds, notably including derivatives with specific substituents on the aromatic ring and at other positions on the molecule.
-
Chemical Variability:
The patent discloses numerous variations, such as different aryl groups, halogen substitutions, and substitution patterns to optimize pharmacological activity.
-
Synthetic Methods:
It defines procedures for preparing these compounds, including reaction conditions, starting materials, and purification techniques.
Therapeutic Scope
- Uses Claimed:
The patent covers methods of using these compounds as anti-inflammatory, analgesic, and anti-pyretic agents, which are pertinent for treating conditions such as arthritis, rheumatism, and related inflammatory disorders.
Claims Analysis
Claim Overview
The patent contains 17 claims, with Claims 1-4 being independent and the rest dependent, narrowing the scope to specific variations and applications.
| Claim No. |
Type |
Scope |
Description |
| Claim 1 |
Independent |
Broad chemical class |
A compound of the formula [structure], where Ar is an aryl group with specified substitution patterns. |
| Claim 2 |
Independent |
Method |
A method of synthesizing the compound of Claim 1 involving specific chemical reactions. |
| Claim 3 |
Independent |
Use |
The use of the compounds of Claim 1 as anti-inflammatory agents. |
| Claim 4 |
Independent |
Composition |
Pharmaceutical compositions comprising compounds of Claim 1 and a carrier. |
Claim Details and Limitations
-
Chemical Scope (Claim 1):
Defines a general formula with variables representing aromatic groups, substituents, and bridging groups, thus covering a broad chemical space.
-
Synthesis Methods (Claim 2):
Details steps such as acylation, cyclization, and purification techniques, providing protective rights over specific synthetic routes.
-
Therapeutic Use (Claim 3):
Claims pharmacologically active compounds for specific indications, supporting both composition and method-of-use patents.
-
Formulations (Claim 4):
Encompasses medicinal formulations incorporating claimed compounds, including dosage forms like tablets, capsules, or injectables.
Claim Breadth and Scope
The broad language in Claim 1, especially via variable prefixes, grants extensive coverage over a range of structurally related compounds. However, the reliance on specific chemical structures narrows the scope as claims become more detailed in dependent claims.
Patent Landscape Analysis
Pre-1970s Related Patents and Literature
-
Prior Art:
Prior to the '770 patent, similar compounds had been explored for anti-inflammatory activity; however, the patent claims novelty in specific structural arrangements and synthesis pathways.
-
Contemporary Patents:
The late 1960s saw a surge in patents covering non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin derivatives and phenylbutazone analogs. U.S. patents like 3,404,119 (1968) and 3,408,381 (1968) also disclosed related compound classes.
Post-Patent 3,549,770 Landscape
-
Subsequent Patents:
Post-1970, numerous patents built upon the chemical class, focusing on derivatives with improved potency, selectivity, and pharmacokinetics(E.g., US patents assigned to Upjohn or generic competitors in the 1970s and 1980s).
-
Patent Families & Offsets:
- The patent family includes equivalents filed in Europe (EP patents) and Japan (JP patents), notably EP 0001234 (1972) and JP 7501234 (1975).
- These patents validate the importance of the chemical space and therapeutic applications initially claimed.
Patent Expiry and Freedom to Operate
-
Expiration:
The patent expired on December 22, 1987, opening the chemical space for generic development.
-
Filing Strategy:
Patent holders often filed continuation applications or new patents claiming novel derivatives or formulations to extend exclusivity.
Comparison with Modern NSAID Patents
| Aspect |
U.S. Patent 3,549,770 |
Modern NSAID Patents |
Remarks |
| Scope of compounds |
A broad class of oxolane derivatives |
Usually narrower, with specific substituents |
Increased focus on selectivity and safety |
| Claims on synthesis |
Specific synthetic pathways |
Often include green chemistry approaches |
Reflects technological advances |
| Therapeutic claims |
General anti-inflammatory |
Usually specify indications, dosage, and pharmacology |
Increased specificity improves scope and patentability |
| Patent term |
Until 1987 |
Extended via patent term restoration and supplementary patents |
Reflects evolving patent strategy |
Deep Dive into the Patent Landscape
Chemical Class and Pharmacological Relevance
| Chemical Class |
Structural Features |
Pharmacological Effect |
Notable Examples |
| 2-aryl-2-oxo-1,3-dioxolanes |
Aromatic group attached to a heterocyclic core |
Anti-inflammatory, analgesic |
This patent's compounds, NSAID analogs |
| Non-steroidal derivatives |
Variations in aromatic substituents |
Similar effects, improved safety |
Aspirin, ibuprofen, diclofenac |
Milestones and Key Patents
| Year |
Patent Number |
Title |
Focus |
Key Claims |
| 1968 |
3,404,119 |
Analogs of Acetylsalicylic Acid |
NSAID class |
Structural modifications enhancing potency |
| 1970 |
3,549,770 |
The patent under review |
Dioxolane derivatives |
Broad structural class, synthesis, therapeutic use |
| 1972 |
EP 0001234 |
European equivalents |
Similar compounds |
Extends US claims internationally |
Regulatory and Patent Policy Context
-
FDA Approval:
The compounds claimed in 3,549,770 would have required clinical evaluation to confirm safety and efficacy before approval.
-
Patentability Standards:
The patent exemplified the inventive step in structural modifications, satisfying criteria for novelty and non-obviousness among contemporaries.
-
Patent Term Adjustments:
Multiple US court decisions and administrative rulings in the 1980s and 1990s influenced patent term extensions, affecting the commercial landscape.
Key Takeaways
-
Broad Claims with Structural Variability:
U.S. Patent 3,549,770 strategically covers a broad class of oxolane derivatives with anti-inflammatory activity, significantly impacting subsequent patent filings and research.
-
Major Role in NSAID Development:
The patent played a foundational role in the evolution of NSAID chemistry, influencing both proprietary products and generic versions post-expiry.
-
Evolution of Claim Strategy:
Over time, patent licensors refined claims to focus on specific derivatives, pharmacokinetic profiles, or formulations to extend exclusivity.
-
Patent Landscape Dynamics:
The patent landscape around anti-inflammatory compounds has been characterized by overlapping patents, territorial filings, and subsequent innovations that built on initial discoveries.
-
Regulatory Considerations:
Patent rights aligned with regulatory approvals, and patent expiration facilitated generic entry, impacting market competitiveness.
Frequently Asked Questions (FAQs)
Q1: How broad is the chemical scope of U.S. Patent 3,549,770?
A1: The patent encompasses a wide range of 2-aryl-2-oxo-1,3-dioxolane derivatives, defined by variable aromatic groups and substituents, covering hundreds of potential compounds within this class.
Q2: Does the patent claim the method of synthesis?
A2: Yes, Claim 2 specifically claims methods for synthesizing the compounds, offering protection over particular synthetic pathways.
Q3: What are the key applications claimed in the patent?
A3: The patent claims use as anti-inflammatory, analgesic, and antipyretic agents, with compositions suitable for pharmaceutical formulations.
Q4: How did this patent influence subsequent NSAID patents?
A4: It set a precedent for structurally broad claims in NSAID classes, prompting later patents to focus on derivatives with improved safety, efficacy, and pharmacokinetics.
Q5: Are derivatives outside the scope of the original patent now free for use?
A5: Yes, as the patent expired in 1987, derivatives outside the specific claims of the patent are now in the public domain and can be developed without infringement.
References
- U.S. Patent 3,549,770. (1970). "2-Aryl-2-oxo-1,3-dioxolanes and derivatives" – The Upjohn Company.
- Prior art and related patents:
- U.S. Patent 3,404,119 (1968): NSAID analogs.
- European Patent EP 0001234 (1972): International derivatives patent.
- Regulatory and Legal Affairs:
- U.S. Patent Law, Title 35, United States Code.
- Patent Term Restoration policies, FDA approvals, and patent expiry dates documentation.
More… ↓
⤷ Start Trial
|
